Skip to main content

Center Publications

Any text in center title
La Banca, R. O., et al. “Play-Based Interventions Delivered By Child Life Specialists: Teachable Moments For Youth With Type 1 Diabetes.”. Journal Of Pediatric Health Care : Official Publication Of National Association Of Pediatric Nurse Associates & Practitioners, pp. 356-365.
Joslin
Roshandel, D., et al. “Dna Methylation Age Calculators Reveal Association With Diabetic Neuropathy In Type 1 Diabetes.”. Clinical Epigenetics, p. 52.
Yale
Tong, X., et al. “Ddb1 E3 Ligase Controls Dietary Fructose-Induced Chrebpα Stabilization And Liver Steatosis Via Cry1.”. Metabolism: Clinical And Experimental, p. 154222.
Michigan
Yang, X., et al. “Coregulator Sin3A Promotes Postnatal Murine Β-Cell Fitness By Regulating Genes In Ca Homeostasis, Cell Survival, Vesicle Biosynthesis, Glucose Metabolism, And Stress Response.”. Diabetes, pp. 1219-1231.
Vanderbilt
Yu, H., et al. “Hypothalamic Pomc Deficiency Increases Circulating Adiponectin Despite Obesity.”. Molecular Metabolism, p. 100957.
Michigan
Ebrahimi, A. G., et al. “Beta Cell Identity Changes With Mild Hyperglycemia: Implications For Function, Growth, And Vulnerability.”. Molecular Metabolism, p. 100959.
Joslin
Miao, Z. -F., et al. “A Metformin-Responsive Metabolic Pathway Controls Distinct Steps In Gastric Progenitor Fate Decisions And Maturation.”. Cell Stem Cell, pp. 910-925.e6.
WUSTL
Caslin, H. L., et al. “Adipose Tissue Macrophages: Unique Polarization And Bioenergetics In Obesity.”. Immunological Reviews, pp. 101-113.
Vanderbilt
Wei, X., et al. “Endothelial Palmitoylation Cycling Coordinates Vessel Remodeling In Peripheral Artery Disease.”. Circulation Research, pp. 249-265.
WUSTL
Jia, T., et al. “Thousands Of Missing Variants In The Uk Biobank Are Recoverable By Genome Realignment.”. Annals Of Human Genetics, pp. 214-220.
UCSD-UCLA
Morozov, D., et al. “Toward Noninvasive Quantification Of Adipose Tissue Oxygenation With Mri.”. International Journal Of Obesity (2005), pp. 1776-1783.
WUSTL
Verma, S., et al. “Empagliflozin Reduces The Risk Of Mortality And Hospitalization For Heart Failure Across Thrombolysis In Myocardial Infarction Risk Score For Heart Failure In Diabetes Categories: Post Hoc Analysis Of The Empa-Reg Outcome Trial.”. Diabetes, Obesity & Metabolism, pp. 1141-1150.
Yale